|
| Waldenström macroglobulinemia – definition, symptoms, and treatment |
| |
| View Full Text View/Add Comment Download reader |
| DOI：10.46701/APJBG.2017042017047 |
| KeyWord:Lymphoplasmacytic lymphoma, mature IgM+ B-lymphocytes, serum paraprotein, Bruton tyrosine kinase, hyperviscosity syndrome |
| Author | Institution |
| Chunyan Gu |
Department of Pathology, The University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, 52242 Iowa, USA; |
| Ye Yang |
School of Medicine and Life Science, Nanjing University of Chinese Medicine, 210023 Nanjing, China; |
| Siegfried Janz |
Department of Pathology, The University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, 52242 Iowa, USA. |
|
| Hits: 1964 |
| Download times: 2384 |
| Abstract: |
| Waldenstr?m macroglobulinemia (WM) is a low-grade lymphoplasmacytic lymphoma of mature IgM+ B-lymphocytes that remains incurable despite recent practice-altering therapeutic advances and refinements in patient care. Defining features of WM include symptoms that can either be attributed to the extent and site of tissue infiltration by tumor cells or the magnitude and immunological specificity of the monoclonal serum IgM (paraprotein). Current guidelines for the therapeutic stratification of patients with newly diagnosed WM recommend BR (bendamustin-rituximab) for bulky and/or symptomatic disease. DRC (dexamethasone-rituximab-cyclophosphamide) is a good treatment option for relapsed or refractory WM. Ibrutinib – a small-drug inhibitor of Bruton tyrosine kinase, approved for WM treatment in the United States and Europe in 2015 – is particularly effective for tumors that harbor the hallmark MYD88L265P mutation. Plasma exchange is indicated in patients with IgM-dependent hyperviscosity syndrome. The potential development of novel drugs and combination regimens generates promise that the future of patients with WM is bright. |
| Close |
|
|
|
